Associated Papers
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.
Lebreton L et al.
Clinical Pharmacology and Therapeutics, 2025
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.
Wang F et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
Apellániz-Ruiz M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
Apellániz-Ruiz M et al.
The Pharmacogenomics Journal, 2015
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.
López Aspiroz E et al.
Clinical Drug Investigation, 2015
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients.
López Aspiroz E et al.
Personalized Medicine, 2014
Slow carbamazepine clearance in a nonadherent Malay woman with epilepsy and thyrotoxicosis.
Yeap LL et al.
Therapeutic Drug Monitoring, 2014
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2008